Applied UV Reports Financial Results for Full Year 2022

Rhea-AI Summary

Applied UV (AUVI) reported a 73% increase in revenue, achieving $20.1 million for 2022 compared to $11.6 million in 2021. This growth was largely driven by its hospitality segment, which saw a 130% rise to $13.6 million due to strategic acquisitions and a rebound in hotel upgrades. The company completed the acquisition of Puro Lighting and LED Supply, effectively doubling its size. However, it faced a net loss of $16.6 million, attributed mainly to a non-cash impairment of goodwill/intangible assets and increased operational costs. Despite challenges, Applied UV anticipates revenue between $45 and $50 million in 2023.

Positive

• Revenue up 73% to $20.1 million in 2022.
• Hospitality segment revenue increased 130% to $13.6 million.
• Acquired Puro Lighting and LED Supply, doubling company size.
• Anticipates revenue of $45 to $50 million in 2023.

Negative

• Net loss increased to $16.6 million in 2022 from $7.4 million in 2021.
• Non-cash impairment charges of $7 million on goodwill/intangibles.
• Gross profit margin dropped from 35.1% to 20.1% year-over-year.

Revenue up 73% to $20.1 Million

MOUNT VERNON, N.Y.--(BUSINESS WIRE)-- Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a global leading provider of patented, scientifically and clinically proven surface and air pathogen elimination and disinfection technologies (fixed, mobile, and HVAC), LED lighting products and premium hotel furnishings, announces today its financial results for the full year 2022.

Recent Business Highlights

• Completed acquisition of Puro Lighting, LLC (“PURO”) and LED Supply Co. (“LED Supply”) effectively doubling the size of the Company, with revenue expected to be between $45 and $50 million in 2023
• Expanded air pathogen elimination and disinfection product offering to include fully integrated systems within systems for facilities HVAC
• Crossed the Bridge to the Internet of Things (“IoT”) - Company expects to incorporate and launch PURONet indoor air monitoring software across all air disinfection devices
• Launched Mt Sinai Lumicide™ Clinical Trial
• Signed strategic manufacturing and related services agreement with Canon Virginia, Inc. (“Canon”), a wholly owned subsidiary of Canon USA to establish Canon as the Company’s primary manufacturer, assembler and logistical authority for its air purification solutions
• Expanded global distribution reach, which now includes 89 dealers and distributors in 52 countries, 47 manufacturing representatives and 19 U.S. based internal sales representatives
• Launched a research collaboration with Johnson Controls, USHIO and Applied UV subsidiary Puro Lighting to study the efficacy and safety of filtered far UV-C disinfection technology
• Strengthened the management team with the addition of Brian Stern and Andrew Lawrence, highly talented and experienced executives from the PURO and LED Supply teams, respectively

Max Munn, CEO of Applied UV, Inc., commented, “2022 was both a difficult year and pivotal year for Applied UV. We acquired Scientific Air late in 2021 with a mobile disinfection product suite that was client centric to one industry and distributor specific to COVID-19. Unfortunately, previous senior management’s focus did not timely re-position the Company to address this. Consequentially, we determined to write down a substantial portion of our investment and put it behind us. In addition, the Company has incurred significant one-time integration and acquisition related costs associated with the more successful acquisitions, thereby exiting 2022 with a Company better positioned to achieve improved results in 2023.

Through strategic transactions and partnerships, we have positioned the Company as a fully integrated solutions provider offering total air and surface pathogen elimination and disinfection platforms, and specialty LED lighting and custom premium furnishings for the hospitality sector. We completed our acquisition of Puro Lighting, LLC (“PURO”) and LED Supply Co. (“LED Supply”), effectively doubling the size of the Company, and signed a strategic manufacturing and related services agreement with a wholly owned subsidiary of Canon USA (“Canon”) to establish Canon as our primary manufacturer, assembler and logistical authority for our air purification solutions. Integration of these assets is progressing, and we are beginning to realize cost savings across all of our divisions.”

Munn continued, “In Pathogen elimination, we recognized the accelerating shift in demand for complete systems within a system solutions that play a more permanent role in improving Indoor Air Quality (IAQ), standards which were outlined by the U.S. Government last year. Increasingly, enterprises are seeking end-to-end systems across entire facilities that include software monitoring capabilities. Accordingly, we altered our marketing, merger and acquisition, and research and development activities as well as accelerated our IoT development, manufacturing processes and next generation product development roadmap.”

Munn continued, “Hospitality is experiencing a rebound as hotels resume scheduled upgrades, remodel, repair and maintenance activities that were postponed due to the pandemic and subsequent closing of the U.S. economy. Hotels are seeking onshore manufacturing alternatives to mitigate supply chain and geopolitical risks, and we have established well-performing manufacturing capabilities that can meet this demand. Our acquisition of VisionMark further enables us to design-assist, fabricate, deliver and install high-end hotel living space furnishings and expands our reach into the luxury hospitality market beyond our core mirror business. Our Hospitality segment revenue was $13.6 million in 2022, up $7.7 million or 130% as compared to the prior year, with approximately 22% of the increase derived from our base MunnWorks business.”

Munn concluded, “Integration of the assets we acquired is progressing, and we are beginning to realize cost savings across all of our divisions. Looking ahead in pathogen elimination and disinfection, we are building a pipeline of new opportunities across a number of verticals, primarily education, food preservation and cannabis, that we believe will drive future growth and improve financial results.”

Segments

The Company has three reportable segments: the design, manufacture, and distribution of disinfecting systems for use in healthcare, hospitality, food preservation, education and winery verticals markets (pathogen elimination and disinfection segment); the manufacture of fine mirrors and furniture specifically for the hospitality industry (hospitality segment); and the corporate segment, which includes expenses primarily related to corporate governance, such as board fees, legal expenses, audit fees, executive management and listing costs.

2022 Summary Financial Results

Net Sales

Net sales of $20.1 million represented an increase of $8.5 million, or 72.6% for the year ended December 31, 2022 as compared to net sales of $11.6 million for the year ended December 31, 2021. This increase was primarily attributable to the hospitality segment, with sales of $13.6 million, representing an increase of $7.7 million, or 129.5%, as compared to 2021. This was largely due to the VisionMark asset acquisition, accounting for $6.0 million of the increase, plus the increase in sales in the base MunnWorks business of $1.7 million, or 28.5%. The hospitality segment is currently experiencing a rebound in the markets it serves due to hotels resuming their scheduled upgrade, remodel and repair and maintenance activities that were postponed due to the COVID-19 pandemic and subsequent closing of the U.S. economy. The pathogen elimination and disinfection segment had sales of $6.5 million in 2022, which represented a 13.6% increase over 2021. The disinfection-related markets have not yet rebounded from the initial “buy-in” during the early stages of the Covid-19 pandemic. Additionally, due to macro market shifts, the Company saw major global trends towards end-to-end systems across entire facilities that include software monitoring capabilities. This allows facilities to implement standards included in the current Environmental Protection Agency (EPA) “Clean The Air” initiatives and guidelines announced in early 2022. These guidelines set the standards that are focused on improving IAQ, including indoor air ventilation and HVAC systems in all public spaces. With these shifting macro trends, the Company altered its marketing, merger and acquisition, and research and development activities to address these changes. Additionally, the Company accelerated its IoT development, manufacturing processes, and next generation product development roadmap. The PURO acquisition, coupled with the strategic manufacturing partnership with Canon, further addresses this shift in focus.

Gross Profit

Gross profit was $4.0 million, which was 20.1% of sales for the year ended December 31, 2022 as compared to $4.1 million, which was 35.1% of sales for the year ended December 31, 2021. Gross profit as a percentage of sales decreased primarily due to the higher sales mix of the hospitality segment. The hospitality segment’s sales for the year ended December 31, 2022 were 67.7% of AUVI’s total as compared to 50.9% for the year ended December 31, 2021. Additionally, the hospitality segment’s gross profit as a percentage of sales decreased from 24.5% for the year ended December 31, 2021 to 9.3% for the year ended December 31, 2022, largely as a result of the lower gross profit on the completion of projects that were in process when the Company acquired the assets of VisionMark, which was a non-recurring event. The Company is focused on streamlining both manufacturing and distribution operations across both segments.

Operating Expenses

Selling, General, and Administrative – S,G&A costs were $14.8 million for the year ended December 31, 2022, which represented an increase of $3.5 million as compared to the year ended December 31, 2021. This increase was driven primarily by the asset acquisitions of VisionMark in the hospitality segment in Q1 2022 and the asset acquisitions of KES Science and Technology (“KES”) and Scientific Air (“SciAir”) in the pathogen elimination and disinfection segment at the end of Q3/beginning of Q4 2021: payroll and sales commission costs increased $1.5 million; amortization costs increased $1.0 million; marketing increased $0.4 million; professional fees increased $0.3 million; rent increased $0.3 million. The Company anticipates efficiency gains in the coming year as all three acquisitions have been fully integrated and synergies are being leveraged.

Loss on Impairment of Goodwill and Intangibles – The Company determined that a triggering event had occurred as a result of a settlement agreement with Scientific Air. A quantitative impairment test on the goodwill determined that the fair value was below the carrying value and as a result the Company recorded a full non-cash goodwill impairment charge of $1.1 million on the Consolidated Statements of Operations for the year ended December 31, 2022. Subsequently, as of December 31, 2022, we evaluated potential triggering events that might be indicators that other Scientific Air intangibles were impaired. We saw a significant decrease in the number of orders and demand of our Scientific Air product lines. As a result of this impact due to the shifting market trends described above in the Net Sales commentary, an additional non-cash impairment on intangibles of $5.9 million was also recorded in the Consolidated Statements of Operations for the year ended December 31, 2022.

Other Income (Expense)

On March 31, 2022, there was a dispute between the Company and Scientific Air (“Old SAM Partners”) regarding certain representations and warranties in the purchase agreement which resulted in a settlement and mutual release agreement pursuant to which Old SAM Partners agreed to relinquish such Old SAM Partners’ right, title, and interest in the previously issued 400,000 shares of AUVI common stock that were part of the consideration in the original asset acquisition. The Company recorded a loss on change in fair market value of contingent consideration of $240,000, and as a result of the settlement, the Company recorded a gain on settlement of $1.7 million during the year ended December 31, 2022. The Company had previously recorded a loss on contingent consideration of $574,000 for the year ended December 31, 2021 as a result of the decrease in our stock price from the date of acquisition of Scientific Air and the reporting date.

Other Income includes $205,000 in the year ended December 31, 2022 for the Employee Retention Tax Credit.

Net Loss

The Company recorded a net loss of $16.6 million for the year ended December 31, 2022, compared to a net loss of $7.4 million for the year ended December 31, 2021. The increase of $9.2 million in the net loss was mainly due to the non-cash Loss on Impairment of Goodwill/Intangibles of $7.0 million and an increase in S,G&A costs of $3.5 million as explained above. Loss per common share is $(1.41) for 2022. Excluding impairment loss, loss per common share is $(0.86) as compared to $(0.86) in 2021.

Liquidity

On July 1, 2022, the Company filed a $50 million shelf registration on Form S-3 with the SEC which allows for flexibility to raise funds as needed. Additionally, in December 2022, the Company entered into a Loan and Security Agreement with Pinnacle Bank, which provides for a $5 million secured revolving credit facility. The Company had approximately $2.7 million of unrestricted cash available on its consolidated balance sheet as of December 31, 2022 compared to $7.9 million as of December 31, 2021.

Conference Call/Webcast Information

Applied UV's management team will host an investor conference call and live webcast at 9 a.m. ET on April 3, 2023.

Investors can access the live webcast via a link on Applied UV's web site or at https://www.webcaster4.com/Webcast/Page/2626/47804.

For those planning to participate on the call, please dial +1-888-506-0062 (for domestic calls), or +1-973-528-0011 (for international calls), passcode 115108.

A replay of the conference call will be available online on the Applied UV web site, and a dial-in replay will be available for one week following the call at +1-877-481-4010 (for domestic calls) or +1-919-882-2331 (for international calls), replay passcode 47804.

Follow us on Twitter

About Applied UV

Applied UV, Inc. (“AUVI”) provides proprietary surface and air pathogen elimination and disinfection technology focused on Improving Indoor Air Quality (IAQ), specialty LED lighting and luxury mirrors and commercial furnishings all of which serves clients globally in both the commercial and retail segments.

Our products address the needs in the healthcare, hospitality, food preservation, cannabis, education, winery vertical markets. The Company has established strategic manufacturing partnerships and alliances including Canon Virginia Inc, Acuity Brands Lighting, Johnson Controls International, Siemens, W.W. Grainger, and a global network of 89 dealers and distributors in 52 countries, offering a complete suite of products through its two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“MunnWorks”). SteriLumen owns brands and markets a portfolio of clinically proven products utilizing advanced UVC Carbon, Broad Spectrum UVC LED’s, Photo-catalytic oxidation (PCO) pathogen elimination technology, branded Airocide ™, Scientific Air™, Airoclean™ 420, Lumicide™, PUROHealth, PURONet, and LED Supply Co. SteriLumen’s proprietary platform suite of patented, surface and air technologies offers, the most complete pathogen disinfection platform including mobile, fixed and HVAC systems and software solutions interconnecting its entire portfolio suite into the IoT allowing customers to implement, manage and monitor IAQ measures recommended by the EPA across any enterprise. SteriLumen’s Lumicide™ platform applies the power of ultraviolet light (UVC) to destroy pathogens automatically, addressing the challenge of healthcare-acquired infections (HAIs) in several patented designs for infection control in healthcare. LED Supply Company, is a full-service, wholesale distributor of LED lighting and controls used throughout facilities in North America.

MunnWorks manufactures and sells custom luxury and backlit mirrors, and conference room and living spaces furnishings.

Our global list of Fortune 100 end users including Kaiser Permanente, NY Health+Hospitals, MERCY Healthcare, Baptist Health South Florida, New York City Transit, Samsung, JB Hunt, Boston Red Sox’s Fenway Park, JetBlue Park, France’s Palace of Versailles, Whole Foods, Del Monte Foods, U.S. Department of Veterans Affairs, Marriott, Hilton, Four Seasons and Hyatt, and more. For information on Applied UV, Inc., and its subsidiaries, please visit https://www.applieduvinc.com.

Forward-Looking Statements

The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company’s current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

Applied UV, Inc. and Subsidiaries
Consolidated Balance Sheets
As of December 31, 2022 and 2021
	2022				2021
Assets
Current Assets
Cash and cash equivalents	$	2,734,485			$	7,922,906
Restricted cash		—				845,250
Accounts receivable, net of allowance for doubtful accounts		1,508,239				986,253
Costs and estimated earnings in excess of billings		1,306,762				—
Inventory, net		5,508,086				1,646,238
Vendor deposits		75,548				992,042
Prepaid expense and other current assets		1,187,223				419,710
Total Current Assets		12,320,343				12,812,399
Property and equipment, net of accumulated depreciation		1,133,468				196,611
Goodwill		3,722,077				4,809,811
Other intangible assets, net of accumulated amortization		11,354,430				18,976,556
Other assets		153,000				—
Right of use assets		4,044,109				1,730,615
Total Assets	$	32,727,427			$	38,525,992
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued expenses	$	2,982,760			$	1,642,108
Contingent Consideration		—				1,460,000
Deferred revenue		4,730,299				788,776
Due to landlord (Note 2)		229,234				—
Warrant liability		9,987				68,263
Financing lease obligations		33,712				7,671
Operating lease liability		1,437,308				389,486
Notes payable		2,098,685				97,500
Total Current Liabilities		11,521,985				4,453,804
Long-term Liabilities
Due to landlord-less current portion (Note 2)		393,230				—
Notes payable- less current portion		765,144				60,000
Financing lease obligations-less current portion		158,070				—
Operating lease liability-less current portion		2,655,103				1,346,428
Total Long-Term Liabilities		3,971,547				1,406,428
Total Liabilities		15,493,532				5,860,232
Stockholders’ Equity
Preferred stock, Series A Cumulative Perpetual, $0.0001 par value, 19,990,000 shares authorized, 552,000 shares issued and outstanding as of both December 31, 2022 and 2021		55				55
Preferred stock, Series X, $0.0001 par value, 10,000 shares authorized, 10,000 shares issued and outstanding as of December 31, 2022 and 2,000 shares issued and outstanding as of December 31, 2021		1				1
Common stock $.0001 par value, 150,000,000 shares authorized; 13,676,450 shares issued and outstanding as of December 31, 2022 and 12,775,674 shares issued and outstanding as of December 31, 2021		1,368				1,278
Additional paid-in capital		45,619,670				42,877,622
Treasury stock at cost, 113,485 and 0 shares, respectively		(149,686	)			—
Accumulated deficit		(28,237,513	)			(10,213,196	)
Total Stockholders’ Equity		17,233,895				32,665,760
Total Liabilities and Stockholders’ Equity	$	32,727,427			$	38,525,992

Applied UV, Inc. and Subsidiaries
Consolidated Statements of Operations
For the Years Ended December 31, 2022 and 2021
	2022				2021
Net Sales	$	20,139,849			$	11,667,579
Cost of Goods Sold		16,101,555				7,569,193
Gross Profit		4,038,294				4,098,386
Operating Expenses
Research and development		319,167				53,408
Selling general and administrative		14,804,068				11,341,712
Loss on impairment of goodwill and intangible assets		6,993,075				—
Total Operating Expenses		22,116,310				11,395,120
Operating Loss		(18,078,016	)			(7,296,734	)
Other Income (Expense)
Change in Fair Market Value of Warrant Liability		58,276				66,862
Interest expense		(290,341	)			—
Loss on change in Fair Market Value of Contingent Consideration		(240,000	)			(574,000	)
Gain on Settlement of Contingent Consideration (Note 2)		1,700,000				—
Other Income		274,764				24,871
Forgiveness of paycheck protection program loan		—				296,827
Total Other Income (Expense)		1,502,699				(185,440	)
Loss Before Provision for Income Taxes		(16,575,317	)			(7,482,174	)
Benefit from Income Taxes		—				(91,819	)
Net Loss	$	(16,575,317	)		$	(7,390,355	)
Net Loss attributable to common stockholders:
Dividends to preferred shareholders		(1,449,000	)			(603,750	)
Net Loss attributable to common stockholders		(18,024,317	)			(7,994,105	)
Basic and Diluted Loss Per Common Share	$	(1.41	)		$	(0.86	)
Weighted Average Shares Outstanding - basic and diluted		12,754,979				9,273,257

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005068/en/

Applied UV Inc.

Max Munn

Applied UV Founder, CEO & Director

Max.munn@applieduvinc.com

Investor Relations Contact:

Brett Maas, Managing Principal

Hayden IR

brett@haydenir.com

(646) 536-7331

Source: Applied UV, Inc.

FAQ

What are Applied UV's 2022 financial results?

Applied UV reported revenues of $20.1 million for 2022, a 73% increase from 2021.

What is Applied UV's revenue guidance for 2023?

Applied UV anticipates revenue between $45 and $50 million for 2023.

What led to the increase in Applied UV's net loss in 2022?

The net loss increased to $16.6 million mainly due to non-cash impairment charges and higher operating costs.

How did the hospitality segment perform in 2022?

The hospitality segment revenue increased by 130% to $13.6 million in 2022.

What acquisitions did Applied UV complete recently?

Applied UV completed the acquisition of Puro Lighting and LED Supply, doubling its size.